eEF2K Antibody (B-4): sc-393366

eEF2K Antibody (B-4) is a mouse monoclonal IgG2a antibody that detects eEF2K in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). eEF2K, or eukaryotic elongation-factor-2 kinase, plays a crucial role in regulating protein synthesis by phosphorylating and inactivating eEF2, thereby modulating the rate of polypeptide chain elongation during translation. This regulation is vital for cellular responses to various stimuli, including stress and growth factors, as anti-eEF2K antibody (B-4) allows cells to adapt their protein synthesis rates according to metabolic needs. eEF2K is predominantly located in the cytoplasm, where eEF2K interacts with calcium and calmodulin, which are essential for activation. Notably, eEF2K undergoes post-translational modifications, including phosphorylation at specific serine residues, which further influence activity and stability. For instance, phosphorylation at Ser 359 and Ser 366, induced by factors such as insulin-like growth factor-1 and p70 S6 kinase, respectively, leads to inactivation of eEF2K, particularly under low calcium conditions. This intricate regulation underscores the importance of eEF2K in maintaining cellular homeostasis and responding to environmental changes, making eEF2K (B-4) antibody an invaluable tool for researchers studying translation control and its implications in various physiological and pathological processes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

eEF2K Antibody (B-4) References:

1. MicroRNA-877 acts as a tumor suppressor by directly targeting eEF2K in renal cell carcinoma.  |  Shi, Q., et al. 2016. Oncol Lett. 11: 1474-1480. PMID: 26893763
2. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.  |  Pan, Z., et al. 2018. Eur J Med Chem. 144: 517-528. PMID: 29288948
3. Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.  |  Bircan, HA., et al. 2018. Lung Cancer. 124: 31-39. PMID: 30268477
4. Designing an eEF2K-Targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells.  |  Liu, Y., et al. 2020. Eur J Med Chem. 204: 112505. PMID: 32717479
5. eEF2K as a novel metastatic and prognostic biomarker in gastric cancer patients.  |  Jiang, M., et al. 2021. Pathol Res Pract. 225: 153568. PMID: 34352439
6. EEF2K silencing inhibits tumour progression through repressing SPP1 and synergises with BET inhibitors in melanoma.  |  Deng, G., et al. 2022. Clin Transl Med. 12: e722. PMID: 35184394
7. Increased eEF2K Promotes Glycolysis and Aggressive Behaviors of Fibroblast-Like Synoviocytes in Rheumatoid Arthritis.  |  Chen, D., et al. 2022. J Inflamm Res. 15: 1729-1744. PMID: 35300214
8. Discovery of New Inhibitors of eEF2K from Traditional Chinese Medicine Based on In Silico Screening and In Vitro Experimental Validation.  |  Fu, Q., et al. 2022. Molecules. 27: PMID: 35956836
9. Impact of silencing eEF2K expression on the malignant properties of chordoma.  |  Aydemir, E., et al. 2023. Mol Biol Rep. 50: 3011-3022. PMID: 36652154
10. Enhanced NK cell activation via eEF2K-mediated potentiation of the cGAS-STING pathway in hepatocellular carcinoma.  |  Xu, Y., et al. 2024. Int Immunopharmacol. 129: 111628. PMID: 38320351

The preferred eEF2K antibody is eEF2K Antibody (C-12): sc-390710.